The development of tyrosine kinase inhibitors (TKIs) has led to extended lifespans for many
patients with chronic myelogenous leukemia (CML). However, 20% to 30% of patients fail to …

Membrane proteins are involved in the prognosis of the most common forms of cancer.
Membrane proteins are the hallmark of a cancer cell. The overexpressed membrane …

Chronic myeloid leukemia (CML), which is characterized by the Philadelphia translocation,
which fuses breakpoint cluster region (BCR) sequences from chromosome 22 upstream of …

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder. Current targeted
therapies designed to inhibit the tyrosine kinase activity of the BCR‐ABL oncoprotein have …

Tyrosine kinase inhibitor (TKI) resistance is a major problem in chronic myeloid leukemia
(CML). We generated a TKI-resistant K562 sub-population, K562-IR, under selective …

This book explores outcome modeling in cancer from a data-centric perspective to enable a
better understanding of complex treatment response, to guide the design of advanced …

Chronic myeloid leukemia (CML) is a stem cell disorder characterized by unrestricted
proliferation of the myeloid series that occurs due to the BCR-ABL fusion oncogene as a …

Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by a unique
BCR-ABL fusion gene. Tyrosine kinase inhibitors (TKIs) were developed to target the BCR …

The archetype driving the drug targeting approach to cancer therapy is the success of
imatinib against chronic phase chronic myeloid leukemia (CML‐CP). Molecular targeting …

Leukemias arise from genetic alterations in normal hematopoietic stem or progenitor cells,
leading to impaired regulation of proliferation, differentiation, apoptosis, and survival of the …